Jubilant

Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
Credit, PRMT5, Therapeutic index, Conference, Cancer, IND, Company, Therapy, Degenerative disease, Patient, Credit Suisse, Jubilant, Pharmaceutical industry

Its advanced structure based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships including with Blueprint Medicines.

Key Points: 
  • Its advanced structure based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships including with Blueprint Medicines.
  • The Company's pipeline, consists of a first-in-class dual epigenetic modifier, JBI-802, currently in a Phase I/II clinical trial to treat solid tumors, a novel brain-penetrant modulator of PRMT5 for which an IND has been accepted, brain penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications.
  • The Company is headquartered in Bedminster, New Jersey and guided by globally renowned scientific advisors.
  • For more: www.jubilanttx.com , Twitter @JubilantTx , LinkedIn

Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

Retrieved on: 
Wednesday, August 3, 2022
SAM, Algorithm, US FDA, Phase, Brain, Investigational New Drug, PRMT5, Jubilant, Degenerative disease, Food, Patient, Company, CNS, Disease, Cancer, JBI, Pharmacokinetics, Metastasis, Therapy, Incidence, Food and Drug Administration, US, Medical imaging, Pharmaceutical industry, IND

Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. shared on the announcement,"JBI-778 will be our second, highly selective oral drug candidate to enter clinical development following JBI-802.

Key Points: 
  • Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. shared on the announcement,"JBI-778 will be our second, highly selective oral drug candidate to enter clinical development following JBI-802.
  • These two programs, along with several others partnered or in preclinical development, highlight Jubilant Therapeutics' proven discovery engine and structure-based drug discovery expertise."
  • Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. said,"JBI-778was engineered by our drug discovery team to be a PRMT5 substrate-competitive and brain penetrant drug candidate to address primary brain tumors and brain metastases which currently have limited treatment options.
  • JBI-778 is a potent and selective brain penetrant inhibitor of protein arginine methyl transferase 5 (PRMT5), which is overexpressed in many cancers.

Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

Retrieved on: 
Wednesday, August 3, 2022
SAM, Algorithm, US FDA, Phase, Brain, Investigational New Drug, PRMT5, Jubilant, Degenerative disease, Food, Patient, Company, CNS, Disease, Cancer, JBI, Pharmacokinetics, Metastasis, Therapy, Incidence, Food and Drug Administration, US, Medical imaging, Pharmaceutical industry, IND

Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. shared on the announcement,"JBI-778 will be our second, highly selective oral drug candidate to enter clinical development following JBI-802.

Key Points: 
  • Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. shared on the announcement,"JBI-778 will be our second, highly selective oral drug candidate to enter clinical development following JBI-802.
  • These two programs, along with several others partnered or in preclinical development, highlight Jubilant Therapeutics' proven discovery engine and structure-based drug discovery expertise."
  • Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. said,"JBI-778was engineered by our drug discovery team to be a PRMT5 substrate-competitive and brain penetrant drug candidate to address primary brain tumors and brain metastases which currently have limited treatment options.
  • JBI-778 is a potent and selective brain penetrant inhibitor of protein arginine methyl transferase 5 (PRMT5), which is overexpressed in many cancers.

Enavate Sciences Appoints Industry Veteran Robert Glassman as Executive Vice President, Search & Evaluation

Retrieved on: 
Monday, July 11, 2022
Partnership, Health, Harvard Medical School, McKinsey & Company, Industry, Medication, Bank, Therapy, Merrill (company), Company, Environment, Faculty, Umoja, Investment, Vice, Weill Cornell Medicine, Credit Suisse, Harvard College, Ridgemont Equity Partners, ENAV, Bank of America, Growth, Clinical, Medicine, Pharmaceutical industry, Medicine, Jubilant

MENLO PARK, Calif., July 11, 2022 /PRNewswire/ -- Enavate Sciences , a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation.

Key Points: 
  • MENLO PARK, Calif., July 11, 2022 /PRNewswire/ -- Enavate Sciences , a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation.
  • "I'm excited to contribute to Jim's vision for Enavate and work closely with the Patient Square team to advance the platform.
  • Dr. Glassman is an industry veteran with nearly 30 years of health care leadership and investment experience.
  • Patient Square invests in businesses that strive to improve patient lives, strengthen communities and create a healthier world.

Jubilant HollisterStier LLC enters into cooperative agreement of $149.6 Mn with US Government to expand critical vaccine manufacturing capacity

Retrieved on: 
Monday, May 30, 2022
Department, HHS, Army Contracting Command, Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical and Biological Defense, RNA transfection, Contract, Company, Social media, Army, Slave & Otis, Environment, JHS, DOD, Vaccine, Government, Therapy, Human services, API, USD, Department of Defence, Radiopharmaceutical, COVID-19, Research, CBRN, American Rescue Plan Act of 2021, Contract manufacturing organization, Pandemic, Jubilant, United States Joint Forces Command, Contract research organization, JPL, CMO, Choice, Degenerative disease, NHS Gender Identity Development Service, Globe, Development, Acquisition, BARDA, CEO, Fine chemical, Biotechnology, NOIDA, Medication, Radiation

Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.

Key Points: 
  • Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.
  • We are proud to support the US government in their efforts of making the US more prepared and ready for future pandemics."
  • Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids.
  • With facilities in North America, Jubilant HollisterStier LLC provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries.

Jubilant HollisterStier LLC enters into cooperative agreement of $149.6 Mn with US Government to expand critical vaccine manufacturing capacity

Retrieved on: 
Monday, May 30, 2022
Department, HHS, Army Contracting Command, Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical and Biological Defense, RNA transfection, Contract, Company, Social media, Army, Slave & Otis, Environment, JHS, DOD, Vaccine, Government, Therapy, Human services, API, USD, Department of Defence, Radiopharmaceutical, COVID-19, Research, CBRN, American Rescue Plan Act of 2021, Contract manufacturing organization, Pandemic, Jubilant, United States Joint Forces Command, Contract research organization, JPL, CMO, Choice, Degenerative disease, NHS Gender Identity Development Service, Globe, Development, Acquisition, BARDA, CEO, Fine chemical, Biotechnology, NOIDA, Medication, Radiation

Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.

Key Points: 
  • Speaking on the announcement, Pramod Yadav, CEO, Jubilant Pharma Limited said,"Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers.
  • We are proud to support the US government in their efforts of making the US more prepared and ready for future pandemics."
  • Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids.
  • With facilities in North America, Jubilant HollisterStier LLC provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries.

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

Retrieved on: 
Monday, April 11, 2022
Company, Cancer, Therapy, LinkedIn, Stroke, PRMT5, Degenerative disease, Thrombosis, Jubilant, Pre-eclampsia, Breast, AACR, Program, CDT, American Association, Metastasis, Chromatin, Citrulline, NETS, Poster, Inflammation, Association, Twitter, Pathway, Drug discovery, Neutrophil, Fibrosis, American Association for Cancer Research, Neutrophil extracellular traps, Algorithm, Pharmaceutical industry, Vaccine

The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.

Key Points: 
  • The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.
  • The first-in-class mechanism of PAD4 inhibition reduces neutrophil extra-cellular traps (NETs) which stimulates cancer cell adhesion, migration and invasion.
  • Jubilant Therapeutics Inc's drug discovery platform created a number of lead molecules with strong in vitro potency and high selectivity to PAD4 compared to PAD1, PAD2 or PAD3.
  • Jubilant Therapeutics Inc. is headquartered in Bedminster, NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

Retrieved on: 
Monday, April 11, 2022
Company, Cancer, Therapy, LinkedIn, Stroke, PRMT5, Degenerative disease, Thrombosis, Jubilant, Pre-eclampsia, Breast, AACR, Program, CDT, American Association, Metastasis, Chromatin, Citrulline, NETS, Poster, Inflammation, Association, Twitter, Pathway, Drug discovery, Neutrophil, Fibrosis, American Association for Cancer Research, Neutrophil extracellular traps, Algorithm, Pharmaceutical industry, Vaccine

The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.

Key Points: 
  • The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.
  • The first-in-class mechanism of PAD4 inhibition reduces neutrophil extra-cellular traps (NETs) which stimulates cancer cell adhesion, migration and invasion.
  • Jubilant Therapeutics Inc's drug discovery platform created a number of lead molecules with strong in vitro potency and high selectivity to PAD4 compared to PAD1, PAD2 or PAD3.
  • Jubilant Therapeutics Inc. is headquartered in Bedminster, NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022

Retrieved on: 
Thursday, March 10, 2022
AACR, Metastasis, Twitter, Chromatin, Therapy, Pre-eclampsia, Citrulline, Immunosuppression, Cancer, PRMT5, Neutrophil, Degenerative disease, Thrombosis, Algorithm, American Association, Jubilant, Fibrosis, Association, Neutrophil extracellular traps, Program, NETS, Stroke, LinkedIn, Pharmaceutical industry

The meeting will be held at the American Association of Cancer Research Annual (AACR) in New Orleans between April 8 to 13, 2022, both in person and virtually.

Key Points: 
  • The meeting will be held at the American Association of Cancer Research Annual (AACR) in New Orleans between April 8 to 13, 2022, both in person and virtually.
  • Details of the presentation are as follows:
    Peptidyl Arginine Deiminase type-4 (PAD4) is an enzyme that converts protein arginine or mono-methylarginine to citrulline.
  • NETs have been shown to be associated with several pathological processes including cancer metastasis, fibrosis, ischemic stroke, preeclampsia, thrombosis and other autoimmune diseases.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.

Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022

Retrieved on: 
Thursday, March 10, 2022
AACR, Metastasis, Twitter, Chromatin, Therapy, Pre-eclampsia, Citrulline, Immunosuppression, Cancer, PRMT5, Neutrophil, Multimedia, Degenerative disease, Thrombosis, Algorithm, American Association, Jubilant, Fibrosis, Association, Neutrophil extracellular traps, Program, NETS, Stroke, View, LinkedIn, Pharmaceutical industry

The meeting will be held at the American Association of Cancer Research Annual (AACR) in New Orleans between April 8 to 13, 2022, both in person and virtually.

Key Points: 
  • The meeting will be held at the American Association of Cancer Research Annual (AACR) in New Orleans between April 8 to 13, 2022, both in person and virtually.
  • Details of the presentation are as follows:
    Peptidyl Arginine Deiminase type-4 (PAD4) is an enzyme that converts protein arginine or mono-methylarginine to citrulline.
  • NETs have been shown to be associated with several pathological processes including cancer metastasis, fibrosis, ischemic stroke, preeclampsia, thrombosis and other autoimmune diseases.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.